School of Biomedical Engineering, Department of Chemical Engineering, McMaster University, 1280 Main St. W., Hamilton, ON L8S 4K1, Canada.
Biomaterials. 2010 Mar;31(8):2399-407. doi: 10.1016/j.biomaterials.2009.11.108. Epub 2009 Dec 22.
Posterior capsule opacification (PCO) or secondary cataract formation, following intraocular lens implantation, is a significant complication affecting an estimated 28% of cataract patients. Matrix metalloproteinases (MMPs) have been demonstrated to play a role in the formation of anterior subcapsular cataracts and it has been shown that the presence of MMP inhibitors (MMPI) decreases subcapsular cataract formation ex vivo. Since the mechanisms responsible for anterior subcapsular cataract formation and posterior capsule opacification are similar, it is reasonable to suggest that MMP inhibitors may also mitigate PCO. One of the most effective ways of delivering the inhibitors may be from the implanted intraocular lens (IOL) material itself. In the current work, delivery of three different MMP inhibitors from silicone rubber as a model IOL material was examined. Loading methods were developed which allowed continuous release of active MMPI for periods of over 5 months in some cases. Reduced migration rates were observed in human lens epithelial cells in vitro, suggesting that an effect on PCO may be possible. While further studies are necessary to tune the systems to achieve the desired rates of release, this work demonstrates that delivery of MMPI from silicone IOL materials has the potential to decrease the incidence of PCO.
后囊混浊（PCO）或继发性白内障形成，在眼内晶状体植入后，是一个显著的并发症，估计影响了 28%的白内障患者。基质金属蛋白酶（MMPs）已被证明在形成前囊下白内障中起作用，并且已经表明 MMP 抑制剂（MMPI）的存在可减少体外的前囊下白内障形成。由于负责前囊下白内障形成和后囊混浊的机制相似，因此可以合理地假设 MMP 抑制剂也可能减轻 PCO。递送抑制剂的最有效方法之一可能是从植入的眼内晶状体（IOL）材料本身。在目前的工作中，研究了三种不同的 MMP 抑制剂从硅橡胶作为模型 IOL 材料的递送。开发了加载方法，允许在某些情况下超过 5 个月的时间内持续释放活性 MMPI。在体外观察到人类晶状体上皮细胞的迁移率降低，这表明可能对 PCO 有影响。虽然需要进一步的研究来调整系统以达到所需的释放速度，但这项工作表明，从硅 IOL 材料递送 MMPI 有可能降低 PCO 的发生率。
